Shows
Reimbursement Pathways for Psychedelic TherapiesReimbursement Pathways for Psychedelic TherapiesWelcome to Reimbursement Pathways for Psychedelic Therapies, the podcast that investigates how psychedelics become reimbursed care.I’m Floris Wolswijk, project manager at Delphi and founder of Blossom, and I'm on a journey to investigate how we can get psychedelics to become a part of mainstream healthcare.Each month, I'll interview health economists, payers, drug developers, and policy architects who are shaping tomorrow's market access rules. We'll investigate the clinical evidence, access pathways, and the healthcare systems that need to implement psychedelics.If you research psychedelics, work in policy or reimbursement, or...2025-05-1501 minReimbursement Pathways for Psychedelic TherapiesReimbursement Pathways for Psychedelic Therapies in Europe - Critical Observations from CollaboratorsWelcome to the final chapter of our series on psychedelic therapies in Europe. This episode moves beyond the regulatory and reimbursement pathways discussed in previous chapters to present critical observations from various experts. First, Martin Gisby from Magnetar Access shares his perspective on commercial strategies and reimbursement. He highlights the importance of focusing on smaller patient populations for effective Health Technology Assessments (HTAs) and market access in Europe. Then, Floris Wolswijk from Blossom will discuss capacity constraints in the Netherlands, emphasizing the need for a strategic plan to meet...2025-04-0251 minReimbursement Pathways for Psychedelic TherapiesReimbursement Pathways for Psychedelic Therapies in Europe - Summary of Potential Reimbursement and Access PathwaysIn the penultimate episode of our series on the psychedelic therapy landscape, we explore the practical aspects of reimbursement for psychedelic therapies across Europe. We cover nine different potential pathways, from discussing standard national reimbursement pathways and their limitations to examining modified assessment methods. These include private insurance care, out-of-pocket payments, innovative alternative access pathways, charity-based services, pre-marketing authorisation access, underground use, and cross-border healthcare. We highlight the challenges, opportunities, and necessary adaptations within healthcare systems to make these emerging treatments widely available to patients.2025-04-0252 minReimbursement Pathways for Psychedelic TherapiesReimbursement Pathways for Psychedelic Therapies in Europe - Ensuring Equitable AccessIn Chapter 9 of our series on psychedelic therapies and reimbursement, we discuss the critical challenge of ensuring equitable access. With psychedelic therapies nearing approval in Europe, disparities in access based on income, schedule flexibility, and healthcare connections are evident. This episode highlights the underrepresentation of ethnic minorities, immigrants, and economically disadvantaged groups in clinical trials. We explore financial, cultural, and geographical barriers, examining regulatory challenges, patient selection criteria, and the need for culturally competent care. Practical solutions, policy recommendations, and insights from experts Sergio Perez Rosal, Monnica T. Williams...2025-04-0230 minReimbursement Pathways for Psychedelic TherapiesReimbursement Pathways for Psychedelic Therapies in Europe - Solutions and RecommendationsIn the eighth episode, we take the opposite perspective from our discussion in the last episode on the challenges surrounding psychedelic therapies in Europe. This time, we focus on practical solutions for integrating these therapies into European healthcare systems, presented in Chapter 8: Solutions and Recommendations. We explore strengthening clinical evidence, enhancing economic evaluations, improving regulatory processes, and building treatment infrastructure. Key recommendations are made for various stakeholders including developers, regulators, and insurers. Specific strategies for different countries such as Germany, the UK, the Netherlands, and the Czech Republic are also discussed, alongside insights from...2025-04-0256 minReimbursement Pathways for Psychedelic TherapiesReimbursement Pathways for Psychedelic Therapies in Europe - Challenges and Barriers to ReimbursementIn this episode, we explore Chapter 7: Challenges and Barriers to Reimbursement for psychedelic therapies across Europe. We discuss the complex process of getting these treatments approved and covered by healthcare systems, focusing on the unique issues that arise from their combined use of drugs and structured psychotherapeutic support. Key points include clinical trial design limitations, evidence challenges, economic evaluation complexities, regulatory hurdles, and societal concerns. Interviews with stakeholders highlight the diverse obstacles at each stage of the process, setting the stage for solutions to be discussed in the next...2025-04-0227 minReimbursement Pathways for Psychedelic TherapiesReimbursement Pathways for Psychedelic Therapies in Europe - Reimbursement Landscape in EuropeIn this episode, we move into Chapter 6: Mapping the Reimbursement Landscape in Europe. This chapter explains how the funding systems work in various European countries, highlighting the challenges for new therapies, particularly psychedelics. We discuss the reimbursement processes in Germany, the UK, the Netherlands, and the Czech Republic, detailing how each system handles pricing, national evaluations, and implementation. The episode also covers common elements like pricing regulations, cost-containment strategies, and cooperation at the EU level. Finally, we explore the specific hurdles psychedelic therapies face due to their unique drug-plus-therapy...2025-04-0222 minReimbursement Pathways for Psychedelic TherapiesReimbursement Pathways for Psychedelic Therapies in Europe - Payer and Health Technology AssessmentsIn Chapter 5, we examine the essential process of securing patient access to psychedelic therapies post-regulatory approval by working with Payer and Health Technology Assessment (HTA) bodies. The chapter discusses the importance of demonstrating clinical efficacy through direct comparisons and indirect comparisons when head-to-head trials aren't feasible. It explains how different European countries have unique HTA processes, such as Germany, the UK, the Netherlands, and the Czech Republic, each with distinct requirements for clinical effectiveness and cost-effectiveness. The episode also covers critical components of health economic models, including cost-effectiveness analysis...2025-04-0230 minReimbursement Pathways for Psychedelic TherapiesReimbursement Pathways for Psychedelic Therapies in Europe - Clinical Development of Psychedelic TherapiesIn this episode about Chapter 4, we focus on the Clinical Development of Psychedelic Therapies. We'll explore the fast-evolving clinical landscape, especially in the US, and compare it with Europe where regulatory and clinical frameworks are still forming. Key topics include designing and conducting clinical trials, addressing challenges like functional unblinding and comparator selection, and the crucial role of psychotherapy in these treatments. We also discuss regulatory considerations, patient selection, the importance of long-term efficacy, safety and tolerability, and the role of real-world evidence. Lastly, we'll highlight the necessity of...2025-04-0243 minReimbursement Pathways for Psychedelic TherapiesReimbursement Pathways for Psychedelic Therapies in Europe - Understanding the Drug Development to Reimbursement PathwayIn this episode, we explore Chapter 3 of our report on psychedelics and reimbursement, focusing on the drug development and reimbursement pathway in Europe. We cover the journey from drug discovery and preclinical development through clinical trials, regulatory approval, and the negotiation of pricing and reimbursement. Special considerations for controlled substances and psychedelic therapies are examined in depth. Finally, we introduce health technology assessments and strategies for achieving local market access and patient uptake.(00:00) Introduction to Drug Development and Reimbursement(00:37) Drug Discovery and...2025-04-0251 minReimbursement Pathways for Psychedelic TherapiesReimbursement Pathways for Psychedelic Therapies in Europe - Introduction to Psychedelics and ReimbursementIn Chapter 2 of our series on psychedelic therapies in Europe, we explore the foundational introduction to psychedelics, their history, therapeutic potential, and the current reimbursement landscape. We look into the ancient uses of psychedelics in different cultures, the mid-20th century research surge and subsequent societal backlash, and the modern resurgence driven by new scientific interest. Furthermore, we discuss the phases of psychedelic therapy, the critical role of set and setting, and the rapid symptom reduction observed in clinical trials. Lastly, we examine the...2025-04-0231 minReimbursement Pathways for Psychedelic TherapiesReimbursement Pathways for Psychedelic Therapies in Europe - Executive SummaryWelcome to the first chapter of our in-depth look at the future of mental healthcare in Europe, focusing on the promise and challenges of psychedelic therapies. This episode dives into the Executive Summary of our comprehensive report, discussing the potential of these therapies to revolutionise treatment for mental health disorders such as depression, PTSD, and addictions. We cover key findings from research, reimbursement challenges, and specific insights from various stakeholders. Learn about the evolving regulatory landscape in countries like Germany, the UK, the Netherlands, and the Czech Republic, as...2025-04-0233 min
Over PsychedelicaBetere Psychedelische Ervaringen door Wetenschap en Praktijk | Floris Wolswijk & Lotte BoekhoutWat zegt de wetenschap en professionele praktijk over de pijlers die een positievere ervaring kunnen voorspellen over versterken? Floris Wolswijk is psycholoog en volgt met BlossomAnalysis de globale wetenschap van psychedelica al jaren op de voet. Zijn website en nieuwsbrief hebben wereldwijd duizenden volgers en daarmee weet Floris als geen ander wat globaal onderzoek ons leert. Partner Lotte Boekhout is therapeut en coach. Samen delen zij hun expertise over wetenschappelijke inzichten en methodes uit de GGZ die kunnen bijdragen aan een diepgaande, veiligere en betere psychedelische ervaring.2024-12-071h 09
Podcast Archives | Psychedelics TodayWhy Psychedelic Research is Booming: Current Trends and HurdlesThere is more psychedelic research happening today than ever before, but is anyone collecting it all into one place? And can we find trends in all that data? In this episode, David interviews Floris Wolswijk: senior project manager at Delphi; co-founder of FLO coaching; and founder of Blossom, an online informational hub collecting psychedelic courses, […]
The post Why Psychedelic Research is Booming: Current Trends and Hurdles appeared first on Psychedelics Today.2024-11-0800 min
Podcast Archives | Psychedelics TodayWhy Psychedelic Research is Booming: Current Trends and HurdlesThere is more psychedelic research happening today than ever before, but is anyone collecting it all into one place? And can we find trends in all that data? In this episode, David interviews Floris Wolswijk: senior project manager at Delphi; co-founder of FLO coaching; and founder of Blossom, an online informational hub collecting psychedelic courses, […]
The post Why Psychedelic Research is Booming: Current Trends and Hurdles appeared first on Psychedelics Today.2024-11-0800 min
Psychedelics TodayPT563 – Why Psychedelic Research is Booming: Current Trends and Hurdles, with Floris WolswijkIn this episode, David interviews Floris Wolswijk: senior project manager at Delphi; co-founder of FLO coaching; and founder of Blossom, an online informational hub collecting psychedelic courses, trials, companies, and over 2000 categorized research articles. When Wolswijk began Blossom, he was barely able to fill a weekly newsletter, and now he’s adding a new study nearly every day, perfectly illustrating the exponential growth in psychedelic research. He talks about why so much research is happening (and why more isn’t), the trends he’s seen, the benefit in research changing people’s minds, and what he hopes for in t...2024-11-081h 29
Anti-Hero's JourneyFloris Wolswijk, Founder of Blossom, An Information Hub for the Psychedelic Spacehttps://www.antiherosjourney.com/
Floris Wolswijk is the founder of Blossom. Blossom serves as an informational hub for psychedelic insights, from cutting-edge research to the companies implementing psychedelic-assisted therapy. Floris has also co-founded FLO coaching together with his partner Lotte. They provide psychedelic-assisted coaching with a focus on adequate preparation and integration.
Floris studied Psychology at the Erasmus University in Rotterdam and graduated with a master's degree in 2014. Through his decade of personal experiences with psychedelics and subsequent engagement with scientific literature, he fell in love with the psychedelics field. He is helping make psychedelics more widely available and hopes...2024-01-0134 min
Super PsychedelicIllustrating Psychedelic Insights with Floris WolswijkA quick note before you tune in. We made a survey and a SpeakPipe (think voice messages) to get to know you. Complete either and get 10% off all things Gwella. Get 20% off by leaving us a review (and emailing your screenshot to content@gwellamushrooms.com). Links down below. And now, for the episode…Peter is joined by Floris Wolswijk. Floris is the Founder & Director of Blossom, which helps you find insights on psychedelics as medicine. Through first personal experiences with psychedelics and subsequently an encounter with the scientific literature, he fell in love with the psychedelics field. He...2022-05-2554 min